As an accomplished apoptosis researcher and former CEO of the Sanford-Burnham Medical Research Institute, John Reed has spent much of his career championing academic drug discovery. Last year, however, he started in his new role as Head of Pharma Research & Early Development at Roche, one of the world's largest drug developers. Flush with resources and ideas, he told Asher Mullard about his plans to tweak Roche's therapeutic focus and its approach to clinical development and the externalization of innovation.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
John Reed. Nat Rev Drug Discov 13, 170–171 (2014). https://doi.org/10.1038/nrd4262
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4262
